Search

Displaying results 2191 - 2200 of 3734 in total
  1. Drug

    Insulin peglispro

    go.drugbank.com/drugs/DB11567
    Investigational

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  2. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetocl...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  3. Drug

    Pirarubicin

    go.drugbank.com/drugs/DB11616
    Investigational

    Categories: P-glycoprotein substrates
  4. Drug

    Amenamevir

    go.drugbank.com/drugs/DB11701
    Investigational

    Amenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis, and Safety of Amenamevir.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  5. Drug

    Talinolol

    go.drugbank.com/drugs/DB11770
    Investigational

    Talinolol has been investigated for the basic science of Gastrointestinal Motility Disorder.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Pazufloxacin

    go.drugbank.com/drugs/DB11774
    Investigational

    Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  7. Drug

    Allicin

    go.drugbank.com/drugs/DB11780
    Investigational

    Allicin has been used in trials studying the treatment of Follicular Lymphoma.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  8. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. … [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous

    Categories: Gonadotropin Releasing Hormone Receptor Antagonists, P-glycoprotein inhibitors
  9. Drug

    Valspodar

    go.drugbank.com/drugs/DB11869
    Investigational

    Valspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  10. Drug

    Tetramethrin

    go.drugbank.com/drugs/DB13752
    Experimental

    Categories: P-glycoprotein inhibitors